A different approach consists of iNKT cell activation via targeted delivery of α-GalCer and OVA or tumor self-antigens (PLGA)-based nanoparticles that target the endocytic pathway of the cross-presenting CD8α+ DC subset via DEC205 (39) or Clec9a (40). Here, CD8A is linked to neoplasm.